Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL12 | P48061 | 1/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 9/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 9/20 | 0.58 |
| ▸ | P4HB | P07237 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3737832 | 0.89 | CXCL12 (0.65) | CXCL12CYP1A1CYP1B1P4HBMAOB | |
| SCHEMBL3729579 | 0.83 | CXCL12 (0.71) | CXCL12CYP1A1CYP1B1MAOBMEN1 | |
| SCHEMBL3734789 | 0.83 | CXCL12 (0.71) | CXCL12CYP1A1CYP1B1MAOBMEN1 | |
| SCHEMBL3733240 | 0.82 | P4HB (0.44) | CXCL12CYP1A1CYP1B1P4HBMAOB | |
| SCHEMBL3736318 | 0.82 | LMNA (0.50) | CXCL12CYP1A1CYP1B1MEN1KMT2A | |
| SCHEMBL3735096 | 0.82 | CXCL12 (0.81) | CXCL12CYP1A1CYP1B1MAOBMEN1 | |
| SCHEMBL3737833 | 0.81 | CYP1A1 (0.59) | CXCL12CYP1A1CYP1B1P4HBMAOB | |
| SCHEMBL11816722 | 0.79 | CYP1A1 (0.87) | CXCL12CYP1A1CYP1B1P4HBMAOB | |
| SCHEMBL11816718 | 0.79 | CYP1A1 (0.87) | CXCL12CYP1A1CYP1B1P4HBMAOB | |
| SCHEMBL25193289 | 0.79 | MEN1 (0.69) | CXCL12CYP1A1CYP1B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2114867-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008107335-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | CXCL12 3739/4885CYP1A1 1184/4885CYP1B1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.